Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07147569

TAMBE Japan Post-Marketing Surveillance

To evaluate the safety and efficacy of multi component system (TAMBE device) including GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (Aortic Component; AC) under post-marketing use.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

The Jikei University Hospital, Minatoku, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who were attempted to implant the AC
  • Thoracoabdominal aortic aneurysm
  • Pararenal abdominal aortic aneurysm

Exclusion criteria

  • N/A

Treatment and study plan

GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis

Device

The target patients are those who were attempted to implant the AC during the enrollment period of this surveillance. Patients will also be targeted even if all components of the TAMBE device (devices that can be used in combination with AC specified in IFU) were not used, or if a device other than the component of the TAMBE device was used.

Primary outcomes

  1. Technical Success

    Time frame: From the initial incision or puncture of the access vessel for the implantation procedure to the closure of the access vessel

    Calculate the rate of achievement of technical success at the index procedure. The technical success is defined as follows.

    [Technical success]

    All of the following qualifying criteria are met:

    • Successful access to the access vessels
    • Successful delivery and deployment of AC and all stent grafts used in combination with AC to its intended location
    • Successful side branch delivery catheterization and placement of all stent grafts used in the side branch area to its intended location
    • Absence of type I or type III endoleaks at final completion image evaluation
    • Patency of AC and all stent grafts used in combination with AC at final completion image evaluation
    • Absence of open surgical repair conversion or mortality
  2. Clinical Success

    Time frame: 12 Months

    The achievement rate of clinical success will be calculated. The clinical success is defined as follows.

    [Clinical Success]

    • Achievement of technical success
    • Absence of the events listed below from the time of the index procedure to 12 months after the index procedure
    • Death from the index procedure
    • Death from reintervention
    • Death from aorta-related causes
    • Persistent type I or type III endoleaks
    • Lesion enlargement >5 mm
    • Device migration >10 mm
    • Failure due to device integrity issues
    • Lesion rupture
    • Conversion to open surgical repair
    • Permanent paraplegia
    • Disabling stroke
    • New-onset dialysis
  3. Results related to abdominal branch vessels

    Time frame: 60 Months

    Calculate the incidence of the following events related to abdominal branch vessels (celiac artery, superior mesenteric artery, left/ right renal arteries) or AC and stent grafts used in combination with AC for visceral branch vessels.

    • Primary Patency
    • Primary Assisted Patency
    • Secondary Patency
    • Occlusion
    • Stenosis
    • Kink
    • Target vessel instability
    • Intraprocedural Complications
  4. Major Adverse Events (MAEs)

    Time frame: 60 Months

    The incidence of any of following events is calculated.

    • All-cause mortality
    • Myocardial infarction resulting in death, cardiac arrest, or cardiopulmonary resuscitation
    • Respiratory failure requiring prolonged (> 24 hours) mechanical ventilation or reintubation
    • Renal function decline characterized by one or more of the following:
    • > 50% reduction in pre-treatment Estimated Glomerular Filtration Rate (eGFR)
    • New-onset dialysis
    • Bowel ischemia requiring surgical resection or not resolving with medical therapy
    • Permanent paraplegia
    • Major stroke (Any fatal or disabling stroke).
  5. Thirty-Day Mortality

    Time frame: 30 Days

    Calculate thirty-day mortality. Thirty-day mortality is defined as follows.

    [Thirty-Day Mortality]

    Any death that occurs at the index procedure, within the index procedure hospital stay, or within the first 30 days post-index procedure.

  6. Lesion-Related Mortality

    Time frame: 30 Days

    Calculate lesion-related mortality. Lesion-related mortality is defined as follows.

    [Lesion-related mortality]

    Any death that occurs within the first 30 days, any death that results from lesion rupture, aorta-related adverse events (e.g., infection, occlusion, dissection, hematoma), or adverse events related to a secondary intervention.

  7. Reintervention

    Time frame: 60 Months

    Calculate the incidence of reintervention. Reintervention will be classified as "major" or "minor". Reintervention and its classifications are defined as follows.

    [Reintervention]

    Any procedure after the index procedure on the AC and stent grafts used in combination with AC.

    [Major Reintervention]

    Deployment the stent graft for proximal or distal side, removal of AC and stent grafts used in combination with AC, use of thrombectomy or thrombolysis, and surgical procedure.

    [Minor Reintervention]

    Treatment other than major reintervention that falls under any of the following categories

    • Endovascular procedures (percutaneous transluminal angioplasty, atherectomy, stenting)
    • Interventions to treat branch vessel stenosis
    • Interventions to treat type II endoleaks or branch-related endoleaks.

Study contacts

Contact information is provided by the study sponsor or research team.

Katsuyuki Niwa

CONTACT

[email protected]

+819017754499

Sponsors and collaborators

Lead sponsor

W.L.Gore & Associates

Industry

Collaborators

  • CMIC Co, Ltd. Japan

Registry information

Official study title

GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Marketing Surveillance

Important dates

Study start
2026
Primary completion
2034
Study completion
2034
First posted
Aug 29, 2025
Registry last updated
May 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.